IJCOT-book-cover International Journal of Biotech Trends and Technology  (IJBTT)          
© 2022 by IJBTT Journal
Volume - 12 Issue - 3
Year of Publication : 2022
Authors : Ijaz Sheik, Sri Naga Varun Mutte, Krishna Prasad Davarasingi, Ashok Thulluru
DOI :   10.14445/22490183/IJBTT-V12I3P602

How to Cite?

Ijaz Sheik, Sri Naga Varun Mutte, Krishna Prasad Davarasingi, Ashok Thulluru "Current Review on Nanoparticles Targeting Colorectal Cancer" International Journal of Biotech Trends and Technology  vol. 12, no. 3, pp. 8-17, 2022. Crossref, https://doi.org/10.14445/22490183/IJBTT-V12I3P602 


Despite great advancements in therapy, colorectal cancer (CRC) still causes major morbidity and death and is incredibly common around the world. One of the most promising approaches to treating cancer now involves using nanoparticles as a medication delivery mechanism. Targeted nanoparticles may use chemicals differently expressed on tumour cell surfaces to deliver cytotoxic medications to the tumour effectively. In a number of recent studies, different compounds have been used as ligands on the surfaces of nanoparticles to engage with tumour cells and facilitate the delivery of anticancer medicines. We address the prospective use of ligands and cellular targets in possible techniques for the treatment of CRCs and describe new developments in targeted nanoparticles against CRC in this article.


Chemotherapy, Colorectal cancer, Ligands, stimulation, Targeted nanoparticles.


[1] Freddie Bray, et al., “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394-424, 2018. Crossref, http://doi.org/10.3322/caac.21492
[2] Yang Liu, et al., “Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas,” Cancer Cell, vol. 33, no. 4, pp. 721-735, 2018. Crossref, http://doi.org/10.1016/j.ccell.2018.03.010
[3] Cornelis J A Punt, Miriam Koopman, and Louis Vermeulen, “From Tumour Heterogeneity to Advances in Precision Treatment of Colorectal Cancer,” Nature Reviews Clinical Oncology, vol. 14, no. 4, pp. 235-246, 2017. Crossref, http://doi.org/10.1038/nrclinonc.2016.171
[4] Prof Evelien Dekker, et al., “Colorectal Cancer,” The Lancet, vol. 394, no. 10207, pp. 1467-1480, 2019. Crossref, http://doi.org/10.1016/S0140-6736(19)32319-0
[5] Aaron J Franke, et al., “Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches,” Journal of the National Cancer Institute, vol. 111, no. 11, pp. 1131-1141, 2019. Crossref, http://doi.org/10.1093/jnci/djz093
[6] Eluri Pavitra, et al., “Engineered Nanoparticles for Imaging and Drug Delivery in Colorectal Cancer,” Seminars in Cancer Biology, vol. 69, pp. 293-306, 2021. Crossref, http://doi.org/10.1016/j.semcancer.2019.06.017
[7] Samia Omar, et al., “Colon-Specific Drug Delivery for Mebeverine Hydrochloride,” Journal of Drug Targeting, vol. 15, no. 10, pp. 691-700, 2007. Crossref, http://doi.org/10.1080/10611860701603281
[8] João F Pinto, “Site-Specific Drug Delivery Systems within the Gastro-Intestinal Tract: from the Mouth to the Colon,” International Journal of Pharmaceutics, vol. 395, no. 1-2, pp. 44-52, 2010. Crossref, http://doi.org/10.1016/j.ijpharm.2010.05.003
[9] Bruno A Cisterna, et al., “Targeted Nanoparticles for Colorectal Cancer,” Nanomedicine (Lond), vol. 11, no. 18, pp. 2443-2456, 2016. Crossref, http://doi.org/10.2217/nnm-2016-0194
[10] Herb Brody, “Colorectal Cancer,” Nature, vol. 521, no. 7551, p. S1, 2015. Crossref, http://doi.org/10.1038/521S1a
[11] Rui-Mei Feng, et al., “Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics?,” Cancer Commun (Lond), vol. 39, no. 1, p. 1-12, 2019. Crossref, http://doi.org/10.1186/s40880-019-0368-6 [12] Martin CS Wong, et al., “Prevalence and Risk Factors of Colorectal Cancer in Asia,” Intestinal Research, vol. 17, no. 3, pp. 317- 329, 2019. Crossref, http://doi.org/10.5217/ir.2019.00021
[13] Rebecca L. Siegel, et al., “Colorectal Cancer Statistics, 2020,” CA: A Cancer Journal for Clinicians, vol. 70, no. 3, pp. 145-164, 2020. Crossref, http://doi.org/10.3322/caac.21601
[14] Louis Vermeulen, et al., “Defining Stem Cell Dynamics in Models of Intestinal Tumor Initiation,” Science, vol. 342, no. 6161, pp. 995-998. Crossref, http://doi.org/10.1126/science.1243148
[15] E R Fearon, and B Vogelstein, “A Genetic Model for Colorectal Tumorigenesis,” Cell, vol. 61, no. 5, pp. 759-767, 1990. Crossref, http://doi.org/10.1016/0092-8674(90)90186-i
[16] Nathan R West, et al., “Emerging Cytokine Networks in Colorectal Cancer,” Nature Reviews Immunology, vol. 15, no. 10, pp. 615- 29, 2015. Crossref, http://doi.org/10.1038/nri3896
[17] Caitlin A. Brennan, and Wendy S. Garrett, “Gut Microbiota, Inflammation, and Colorectal Cancer,” Annual Review of Microbiology, vol. 70, pp. 395-411, 2016. Crossref, http://doi.org/10.1146/annurev-micro-102215-095513
[18] J Prados, et al., “Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 8, pp. 1204-1216, 2013. Crossref, http://doi.org/10.2174/18715206113139990325.
[19] Che-Ming Jack Hu, Santosh Aryal, and Liangfang Zhang, “Nanoparticle-Assisted Combination Therapies for Effective Cancer Treatment,” Therapeutic Delivery, vol. 1, no. 2, pp. 323-334, 2010. Crossref, http://doi.org/10.4155/tde.10.13
[20] Andrew Z. Wang, Robert Langer, and Omid C. Farokhzad, “Nanoparticle Delivery of Cancer Drugs,” Annual Review of Medicine, vol. 63, pp. 185-198, 2011. Crossref, http://doi.org/10.1146/annurev-med-040210-162544
[21] Giovanni L. Beretta, and Francesca Cavalieri, “Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy,” Current Medicinal Chemistry, vol. 23, no. 1, pp. 3-22, 2016. Crossref, http://doi.org/10.2174/0929867322666151006094559
[22] Brahmeshwar Mishra, and Sundeep Chaurasia, “Design of Novel Chemotherapeutic Delivery Systems for Colon Cancer Therapy Based on Oral Polymeric Nanoparticles,” Therapeutic Delivery, vol. 8, no. 1, pp. 29-47, 2017. Crossref, http://doi.org/10.4155/tde2016-0058
[23] Treanor D, and Quirke P, “Pathology of Colorectal Cancer,” Clinical Oncology, vol. 19, no. 10, pp. 769-776, 2007. Crossref, http://doi.org/10.1016/j.clon.2007.08.012
[24] Masahiko Tsujii, Sunao Kawano, and Raymond N. DuBois, “Cyclooxygenase-2 Expression in Human Colon Cancer Cells Increases Metastatic Potential,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 3336-3340, 1997. Crossref, http://doi.org/10.1073/pnas.94.7.3336
[25] Weizhen Jia, et al., “Galectin-3 Accelerates M2 Macrophage Infiltration and Angiogenesis in Tumors,” The American Journal of Pathology, vol. 182, no. 5, pp. 1821-1831, 2013. Crossref, http://doi.org/10.1016/j.ajpath.2013.01.017
[26] Ankita Tiwari, et al., “Exploitable Signaling Pathways for the Treatment of Inflammatory Bowel Disease,” Current Signal Transduction Therapy, vol. 12, no. 2, pp. 76-84, 2017. Crossref, http://doi.org/10.2174/1574362412666170330145342
[27] Arvind Gulbake, et al., “Insight to Drug Delivery Aspects for Colorectal Cancer,” World Journal of Gastroenterol, vol. 22, no. 2, pp. 582-599, 2016. Crossref, http://doi.org/10.3748/wjg.v22.i2.582
[28] Walter E.Rudzinski, et al., “Targeted Delivery of Small Interfering RNA to Colon Cancer Cells Using Chitosan and Pegylated Chitosan Nanoparticles,” Carbohydrate Polymers, vol. 147, pp. 323-332, 2016. Crossref, http://doi.org/10.1016/j.carbpol.2016.04.041
[29] Sarbari Acharya, and Sanjeeb K.Sahoo, “PLGA Nanoparticles Containing Various Anticancer Agents and Tumour Delivery by EPR Effect,” Advanced Drug Delivery Reviews, vol. 63, no. 3, pp. 170-83, 2017. Crossref, http://doi.org/10.1016/j.addr.2010.10.008
[30] CristinaLoira-Pastoriza, Julie Todoroff, and Rita Vanbever, “Delivery Strategies for Sustained Drug Release in the Lungs,” Advanced Drug Delivery Reviews, vol. 75, pp. 81-91, 2014. Crossref, http://doi.org/10.1016/j.addr.2014.05.017
[31] Clinical Trials Database: NCT00361842, 2012. [Online]. Available: https://clinicaltrials.gov/ct2/show/NCT00361842
[32] Mukta Paranjpe, and Christel C. Müller-Goymann, “Nanoparticle-Mediated Pulmonary Drug Delivery A Review,” International Journal of Molecular Science, vol. 15, no. 4, pp. 5852-5873, 2014. Crossref, http://doi.org/10.3390/ijms15045852
[33] Xu Wang, et al., “Advances of Cancer Therapy by Nanotechnology,” Cancer Research and Treatment, vol. 41, no. 1, pp. 1-11, 2009. Crossref, http://doi.org/10.4143/crt.2009.41.1.1
[34] Yichao Wang, et al., “Targeted Delivery of 5-Fluorouracil to HT-29 Cells using High Efficient Folic Acid-Conjugated Nanoparticles,” Drug Delivery, vol. 22, no. 2, pp. 191-198, 2015. Crossref, http://doi.org/10.3109/10717544.2013.875603
[35] Puwang Li, et al., “Synthesis and Characterisation of Folate Conjugated Chitosan and Cellular Uptake of its Nanoparticles in HT-29 Cells,” Carbohydrate Research, vol. 346, no. 6, pp. 801-806, 2017. Crossref, http://doi.org/10.1016/j.carres.2011.01.027
[36] Yan Zhang, et al., “Folate-Functionalized Nanoparticles for Controlled 5-Fluorouracil Delivery,” Journal of Colloid and Interface Science, vol. 354, no. 1, pp. 202-209, 2011. Crossref, http://doi.org/10.1016/j.jcis.2010.10.054
[37] Anitha A, et al., “Combinatorial Anticancer Effects of Curcumin and 5-Fluorouracil Loaded Thiolated Chitosan Nanoparticles towards Colon Cancer Treatment,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1840, no. 9, pp. 2730-2743, 2014. Crossref, http://doi.org/10.1016/j.bbagen.2014.06.004.
[38] Wei-Lun, Tang Wei-Hsin, and Tang Shyh-Dar Li, “Cancer Theranostic Applications of Lipid-Based Nanoparticles,” Drug Discovery Today, vol. 23, no. 5, pp. 1159-1166, 2018. Crossref, http://doi.org/10.1016/j.drudis.2018.04.007
[39] Chunhua Yang, and Didier Merlin, “Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy,” Nanomaterials (Basel), vol. 10, no. 7, p. 1424, 2020. Crossref, http://doi.org/10.3390/nano10071424
[40] Christos Tapeinos, Matteo Battaglini, and Gianni Ciofani, “Advances in the Design of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Targeting Brain Diseases,” Journal of Controlled Release, vol. 264, pp. 306–332, 2017. Crossref, http://doi.org/10.1016/j.jconrel.2017.08.033
[41] HouLi Li, et al., “Enhancement of Gastro-Intestinal Absorption of Quercetin by Solid Lipid Nanoparticles,” Journal of Controlled Release, vol. 133, no. 3, pp. 238-44, 2009. Crossref, http://doi.org/10.1016/j.jconrel.2008.10.002
[42] Ming-Yin Shen, et al., “Hierarchically Targetable Polysaccharide-Coated Solid Lipid Nanoparticles as an Oral Chemo/Thermotherapy Delivery System for Local Treatment of Colon Cancer,” Biomaterials, vol. 197, pp. 86-100, 2019. Crossref, http://doi.org/10.1016/j.biomaterials.2019.01.019
[43] Phatsapong Yingchoncharoen, Danuta S. Kalinowski, and Des R. Richardson, “Lipid-Based Drug Delivery Systems in Cancer Therapy: What is Available and what is yet to Come,” Pharmacological Reviews, vol. 68, no. 3, pp. 701-787, 2016. Crossref, http://doi.org/10.1124/pr.115.012070
[44] Gerald Batist, et al., “Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors,” Clinical Cancer Research, vol. 15, no. 2, pp. 692-700, 2009. Crossref, http://doi.org/10.1158/1078-0432.CCR-08-0515
[45] Larissa Kotelevets, et al., “A Squalene-Based Nanomedicine for Oral Treatment of Colon Cancer,” Cancer Research, vol. 77, no. 11, pp. 2964-2975, 2017. Crossref, http://doi.org/10.1158/0008-5472.CAN-16-1741
[46] Mona M. Saber, et al., “Targeting Colorectal Cancer Cell Metabolism through Development of Cisplatin and Metformin NanoCubosomes,” BMC Cancer, vol. 18, no. 1, p. 822, 2018. Crossref, http://doi.org/10.1186/s12885-018-4727-5
[47] Bhupinder S. Sekhon, and Seema R. Kamboj, “Inorganic Nanomedicine--Part 2,” Nanomedicine, vol. 6, no. 5, pp. 612-618. Crossref, http://doi.org/10.1016/j.nano.2010.04.003
[48] Jie Kai Tee, et al., “Nanoparticles’ Interactions with Vasculature in Diseases,” Chemical Society Reviews, vol. 48, pp. 5381–5407, 2019. Crossref, http://doi.org/10.1039/c9cs00309f
[49] Neus Feliu, et al., “In Vivo Degeneration and the Fate of Inorganic Nanoparticles,” Chemical Society Reviews, vol. 45, pp. 2440– 2457, 2016. Crossref, https://doi.org/10.1039/C5CS00699F
[50] Bartosz Klębowski, et al., “Applications of Noble Metal-Based Nanoparticles in Medicine,” International Journal of Molecular Sciences, vol. 19, no. 12, p. 4031, 2018. Crossref, https://doi.org/10.3390/ijms19124031
[51] Behafarid Ghalandari, et al., “The New Insight into Oral Drug Delivery System Based on Metal Drugs in Colon Cancer Therapy Through Β-Lactoglobulin/Oxali-Palladium Nanocapsules,” Journal of Photochemistry and Photobiology B: Biology, vol. 140, pp. 255-265, 2014. Crossref, https://doi.org/10.1016/j.jphotobiol.2014.08.003
[52] Mohammad Azharuddin, et al., “A Repertoire of Biomedical Applications of Noble Metal Nanoparticles,” Chemical Communications, vol. 55, pp. 6964–6996, 2015. Crossref, https://doi.org/10.1039/c9cc01741k
[53] Jihye Yoo, et al., “Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems,” Cancers (Basel), vol. 11, no. 5, p. 640, 2019. Crossref, https://doi.org/10.3390/cancers11050640
[54] Anna Graczyk, et al., “Gold Nanoparticles in Conjunction with Nucleic Acids as a Modern Molecular System for Cellular Delivery,” Molecules, vol. 25, no. 1, p. 204, 2020. Crossref, https://doi.org/10.3390/molecules25010204
[55] Muhamad N, Plengsuriyakarn T, and Na-Bangchang K, “Application of Active Targeting Nanoparticle Delivery System for Chemotherapeutic Drugs and Traditional/Herbal Medicines in Cancer Therapy: A Systematic Review,” International Journal of Nanomedicine, vol. 13, pp. 3921-3935, 2018. Crossref, https://doi.org/10.2147/IJN.S165210
[56] Thijs J. Beldman, et al., “Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis,” ACS Nano, vol. 11, no. 6, pp. 5785–5799, 2017. Crossref, https://doi.org/10.1021/acsnano.7b01385
[57] Jiaqi Xu, et al., “Reversing Tumor Stemness via Orally Targeted Nanoparticles Achieves Efficient Colon Cancer Treatment,” Biomaterials, vol. 216, p. 119247, 2019. Crossref, https://doi.org/10.1016/j.biomaterials.2019.119247
[58] Desai D, et al., “Targeted Modulation of Cell Differentiation in Distinct Regions of the Gastro-Intestinal Tract via Oral Administration of Differently PEG-PEI Functionalised Mesoporous Silica Nanoparticles,” International Journal of Nanomedicine, vol. 11, pp. 299-313, 2016. Crossref, https://doi.org/10.2147/IJN.S94013
[59] Fei Chen, et al., “New Horizons in Tumor Microenvironment Biology: Challenges and Opportunities,” BMC Medicine, vol. 13, p. 45, 2015. Crossref, https://doi.org/10.1186/s12916-015-0278-7
[60] Maonan Wang, et al., “Role of Tumor Microenvironment in Tumorigenesis,” Journal of Cancer, vol. 8, no. 5, pp. 761-773, 2017. Crossref, https://doi.org/10.7150/jca.17648
[61] Johanna A. Joyce, and Jeffrey W. Pollard, “Microenvironmental Regulation of Metastasis,” Nature Reviews Cancer, vol. 9, no. 4, pp. 239-252, 2009. Crossref, https://doi.org/10.1038/nrc2618
[62] Douglas Hanahan, and Robert A. Weinberg, “Hallmarks of Cancer: the Next Generation,” Cell, vol. 144, no. 5, pp. 646-674, 2011. Crossref, https://doi.org/10.1016/j.cell.2011.02.013
[63] Rob A. Cairns, Isaac S. Harris, and Tak W. Mak, “Regulation of Cancer Cell Metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85-95, 2011. Crossref, https://doi.org/10.1038/nrc2981
[64] Jing Yu, Xin Chua, and Yanglong Hou, “Stimuli-Responsive Cancer Therapy Based on Nanoparticles,” Chemical Communication, vol. 50, pp. 11614–11630, 2014. Crossref, https://doi.org/10.1039/c4cc03984j
[65] Jinzhi Du, Lucas A.Lanea, and Shuming Nie, “Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment,” Journal of Controlled Release, vol. 219, pp. 205-214, 2015. Crossref, https://doi.org/10.1016/j.jconrel.2015.08.050
[66] Xiaonan An, et al., “Rational Design of Multi-Stimuli-Responsive Nanoparticles for Precise Cancer Therapy,” ACS Nano, vol. 10, no. 6, pp. 5947–5958, 2016. Crossref, https://doi.org/10.1021/acsnano.6b01296
[67] Taegyu Kang, et al., “Surface Design of Magnetic Nanoparticles for Stimuli-Responsive Cancer Imaging and Therapy,” Biomaterials, vol. 136, pp. 98-114, 2017 Crossref, https://doi.org/10.1016/j.biomaterials.2017.05.013
[68] Ting Wu, and Yun Dai, “Tumor Microenvironment and Therapeutic Response,” Cancer Letters, vol. 387, pp. 61-68, 2017. Crossref, https://doi.org/10.1016/j.canlet.2016.01.043
[69] Rob A. Cairns, Isaac S. Harris, and Tak W. Mak, “Regulation of Cancer Cell Metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85-95, 2011. Crossref, https://doi.org/10.1038/nrc2981
[70] Long Binh Vong, et al., “Development of an Oral Nanotherapeutics using Redox Nanoparticles for Treatment of Colitis-Associated Colon Cancer,” Biomaterials, vol. 55, pp. 54-63, 2015. Crossref, https://doi.org/10.1016/j.biomaterials.2015.03.037
[71] Long Binh Vong, Shinya Kimura, and Yukio Nagasaki, “Newly Designed Silica-Containing Redox Nanoparticles for Oral Delivery of Novel TOP2 Catalytic Inhibitor for Treating Colon Cancer,” Advanced Healthcare Materials, vol. 6, no. 20, 2017. Crossref, https://doi.org/10.1002/adhm.201700428
[72] Manuel Arruebo, Mónica Valladares, and África González-Fernández, “Antibodyconjugated Nanoparticles for Biomedical Applications,” Journal of Nanomaterials, vol. 2009, pp. 1–24, 2009. Crossref, https://doi.org/10.1155/2009/439389
[73] De-Hong Yu, et al., “Peptide-Conjugated Biodegradable Nanoparticles as a Carrier to Target Paclitaxel to Tumor Neovasculature,” Biomaterials, vol. 31, no. 8, pp. 2278-2292, 2010. Crossref, https://doi.org/10.1016/j.biomaterials.2009.11.047
[74] Nora Graf, et al., “α(V)β(3) Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-Tumor Efficacy of a Pt(IV) Prodrug,” ACS Nano, vol. 6, no. 5, pp. 4530-4539. Crossref, https://doi.org/10.1021/nn301148e
[75] Willem JM Mulder, et al., “Magnetic and Fluorescent Nanoparticles for Multimodality Imaging,” Nanomedicine (Lond), vol. 2, no. 3, pp. 307-324, 2007. Crossref, https://doi.org/10.2217/17435889.2.3.307
[76] Ralph Weissleder, et al., “In Vivo Imaging of Tumors with Protease-Activated Near-Infrared Fluorescent Probes,” Nature Biotechnology, vol. 17, no. 4, pp. 375-378, 1999. Crossref, https://doi.org/10.1038/7933
[77] Xiuxia He, et al., “Lectin-Conjugated Fe2O3@Au Core@Shell Nanoparticles as Dual Mode Contrast Agents for in Vivo Detection of Tumor,” Molecular Pharmaceutics, vol. 11, no. 3, pp. 738-745, 2014. Crossref, https://doi.org/10.1021/mp400456j
[78] Daniel R. Larson, et al., “Water-Soluble Quantum Dots for Multiphoton Fluorescence Imaging in Vivo,” Science, vol. 300, no. 5624, pp. 1434-1436, 2003. Crossref, https://doi.org/10.1126/science.1083780
[79] Elias Gounaris, et al., “Fluorescence Endoscopy of Cathepsin Activity Discriminates Dysplasia from Colitis,” Inflammatory Bowel Diseases, vol. 19, no. 7, pp. 1339-1345, 2013. Crossref, https://doi.org/10.1097/MIB.0b013e318281f3f8
[80] Shu-Jyuan Yang, et al., “Folic Acid-Conjugated Chitosan Nanoparticles Enhanced Protoporphyrin IX Accumulation in Colorectal Cancer Cells,” Bioconjugate Chemistry, vol. 21, no. 4, pp. 679-689, 2010. Crossref, https://doi.org/10.1021/bc9004798